Suppliers and packagers for talzenna

talzenna

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651	NDA	Pfizer Laboratories Div Pfizer Inc	0069-0296-30	1 BOTTLE in 1 CARTON (0069-0296-30) / 30 CAPSULE in 1 BOTTLE	2018-10-26
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651	NDA	Pfizer Laboratories Div Pfizer Inc	0069-1195-30	1 BOTTLE in 1 CARTON (0069-1195-30) / 30 CAPSULE in 1 BOTTLE	2018-10-26
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651	NDA	Pfizer Laboratories Div Pfizer Inc	0069-1501-30	1 BOTTLE in 1 CARTON (0069-1501-30) / 30 CAPSULE in 1 BOTTLE	2022-01-31

Suppliers and packagers for talzenna

Last updated: May 31, 2026

TALZENNA (talazoparib) suppliers: Who manufactures the API and finished drug products?

TALZENNA is marketed in the US by Pfizer (brand holder). Talzenna is a small-molecule PARP inhibitor (talazoparib). Supplier and manufacturing responsibility is partitioned across (1) API manufacturers and (2) finished-dose (drug product) manufacturers that are listed in FDA’s Orange Book for each dosage strength and package configuration.

What companies supply the TALZENNA API (talazoparib)?

API supplier identification is typically surfaced via Orange Book “Application Holder” and “Manufacturing Site” listings tied to each NDA/BLA strength. TALZENNA’s Orange Book entries identify firms responsible for manufacturing at specific sites.

How to identify TALZENNA API suppliers in practice

1. Pull the Orange Book listing for TALZENNA (NDA application number), then select the applicable dosage strengths.
2. Review “Applicant” and each listed manufacturing site under the strength.
3. Map manufacturing sites to API versus drug product:
   • Some Orange Book entries list drug product manufacturing sites even when the site also performs API steps.
   • API-only suppliers are more reliably identified via USDMF references, but Orange Book is still the fastest way to get firm-level manufacturing footprints for litigation, qualification, and procurement due diligence.

Which firms manufacture TALZENNA finished drug product (tablets) in the US?

TALZENNA is supplied to US patients as oral tablets. Orange Book listings for each strength identify the drug product manufacturing sites and associated companies that may include:

• Primary commercial manufacture
• Additional backup commercial sites
• Sites used for post-approval manufacturing changes

Dosage forms that appear in TALZENNA supply chains

• Tablets (multiple strengths listed in the Orange Book)

What is the Orange Book status of TALZENNA (NDA listings, strengths, and manufacturing sites)?

Orange Book status matters for supplier assessment because it links:

• Each strength’s regulatory holder
• The associated manufacturing sites
• Any therapeutic equivalence and patent-cover status used by FDA for labeling and generic entry planning

What to look for on the Orange Book entry

• NDA number for talazoparib
• Dosage form and strength
• Applicant
• Manufacturing site(s) per strength

What TALZENNA patent-protected aspects affect supplier qualification and generic sourcing?

Supplier selection is constrained by patent coverage in ways that show up during procurement and competitor sourcing:

• Drug substance (talazoparib) synthesis patents
• Drug product formulation patents (tablet composition, excipient systems, solid-state forms)
• Method-of-use patents (oncology indications and dosing regimens)
• Manufacturing process patents (impurities control, crystallization, polymorph management)

Why this impacts suppliers

• If talazoparib API is protected by composition or process patents, suppliers must license or design around those claims.
• If drug product formulation patents cover key elements, generic and authorized suppliers face formulation change constraints that can affect bioequivalence feasibility.

When does TALZENNA lose exclusivity and how does that affect supplier transitions?

Exclusivity loss and patent expiry drive:

• FDA approval pathway timing for generics and biosimilars-equivalent products (for small molecules, generics)
• Supplier requalification schedules for alternative sources
• Commercial pricing pressure and tendering activity

Practical supply-chain consequence

Once exclusivity/patents end, procurement typically expands to:

• Additional API sources for talazoparib
• Multiple drug product manufacturing sites to support volume and reduce lead-time risk

Which generics or authorized suppliers are likely to try to enter TALZENNA after exclusivity?

Generic entry risk is assessed through:

• Paragraph IV filings (for patent challenges)
• Litigation or settlement timing that can trigger authorized generic or delayed entry
• Whether proposed labeling is compatible with talazoparib’s protected indication and dosing

How to connect entry risk to suppliers

A generic program’s manufacturing plan often identifies:

• API maker(s) (via DMF or public disclosure)
• Tablet press and finishing sites
• Outsourced analytical and stability testing labs that are common across multiple generic filers

What TALZENNA manufacturing/IP barriers exist for new suppliers?

Key barriers for talazoparib supply include:

• IP covering talazoparib (substance and/or process)
• Solid-state and impurity control constraints
• Regulatory quality system requirements for commercial scale manufacturing
• Patent barriers for formulation and method-of-use, which can indirectly block generic development and thereby limit API commercial demand elasticity

How does TALZENNA compare with other PARP inhibitors in supply chain structure?

PARP inhibitor supply chains often include:

• One primary API source plus backup sites
• Separate drug product manufacturers (tablet operations)
• Shared packaging and secondary manufacturing vendors

TALZENNA follows this pattern at the level of Orange Book site listing structure. The differentiator for procurement is whether API and drug product are sourced from the same manufacturing group or split across entities.

Key Takeaways

• TALZENNA is supplied through FDA Orange Book-identified manufacturing sites for each tablet strength, tied to the NDA holder and applicants.
• The fastest defensible way to list talazoparib API versus finished drug product suppliers is to extract TALZENNA’s Orange Book strength-level manufacturing site data and map to DMF-based API responsibility where available.
• Supplier expansion timelines depend on Orange Book patent cover and exclusivity, which in turn affect generic entry and authorized sourcing.

FAQs

1. How do I find TALZENNA manufacturing sites by strength in the Orange Book?
   Use the Orange Book NDA listing for talazoparib, then review each strength’s “manufacturing site” rows.

2. Do TALZENNA tablets use the same manufacturing site for all strengths?
   Orange Book entries often list site(s) per strength; changes in commercial supply can create strength-specific manufacturing footprints.

3. Which documents identify TALZENNA API suppliers more directly than Orange Book?
   USDMF-linked disclosures and supplier qualification packages typically identify API responsibility more precisely than Orange Book manufacturing-site listings.

4. What supplier risks increase during TALZENNA launch-volume spikes?
   Lead-time constraints in API supply, tablet finishing capacity, and stability testing throughput are the usual bottlenecks tied to regulated change control.

5. How do patent challenges affect TALZENNA supplier diversification?
   Paragraph IV challenges and litigation outcomes influence whether generic and authorized suppliers enter, which changes the competitive supplier landscape.

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (TALZENNA (talazoparib) listing pages).